日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Preserving Trial Endpoint Specificity and Cause of Death Attribution in Cardiovascular Trials: Insights From MARINER

在心血管试验中保持试验终点特异性和死亡原因归因:来自 MARINER 研究的启示

Hogan, Shea E; Canonico, Mario Enrico; King, Robert W; Low Wang, Cecilia C; Nehler, Mark R; Parr, Jessica; Rogers, R Kevin; Lu, Wentao; Albanese, John; Barnathan, Elliot S; Spyropoulos, Alex C; Douketis, James D; Bonaca, Marc P; Capell, Warren H

Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial

利伐沙班在接受外周动脉血运重建术后患者中的定量获益-风险评估:VOYAGER PAD试验

Yuan, Zhong; Levitan, Bennett; Deng, Hsiaowei; Szarek, Michael; Bauersachs, Rupert M; Berkowitz, Scott D; Haskell, Lloyd; Barnathan, Elliot S; Bonaca, Marc P

Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials

利伐沙班用于院前 COVID-19 患者的抗血栓预防:两项安慰剂对照试验的荟萃分析

Hsia, Judith; Spyropoulos, Alex C; Piazza, Gregory; Weng, Stephen; Dunne, Michael W; Lipardi, Concetta; Barnathan, Elliot S; Bonaca, Marc P

Primary thromboprophylaxis in ambulatory symptomatic patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

针对门诊有症状的 COVID-19 患者的一级血栓预防:随机对照试验的系统评价和荟萃分析

Di Vece, Davide; Valgimigli, Marco; Barnathan, Elliot; Connors, Jean M; Cools, Frank; Held, Ulrike; Kakkar, Ajay K; Piazza, Gregory; Spirk, David; Virdone, Saverio; Kucher, Nils; Barco, Stefano

Factors associated with early, late, and very late stent thrombosis among patients with acute coronary syndrome undergoing coronary stent placement: analysis from the ATLAS ACS 2-TIMI 51 trial

急性冠脉综合征患者行冠状动脉支架置入术后早期、晚期和极晚期支架血栓形成的相关因素:来自 ATLAS ACS 2-TIMI 51 试验的分析

Chi, Gerald; AlKhalfan, Fahad; Lee, Jane J; Montazerin, Sahar Memar; Fitzgerald, Clara; Korjian, Serge; Omar, Wally; Barnathan, Elliot; Plotnikov, Alexei; Gibson, C Michael

Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness

利伐沙班用于住院后长期血栓预防的获益风险评估

Raskob, Gary E; Ageno, Walter; Albers, Gregory; Elliott, C Gregory; Halperin, Jonathan; Maynard, Gregory; Steg, Philippe Gabriel; Weitz, Jeffrey I; Albanese, John; Yuan, Zhong; Levitan, Bennett; Lu, Wentao; Suh, Eun Young; Spiro, Theodore; Lipardi, Concetta; Barnathan, Elliot S; Spyropoulos, Alex C

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial

利伐沙班联合阿司匹林用于急性重症内科患者的长期血栓预防:来自 MARINER 试验的启示

Spyropoulos, Alex C; Goldin, Mark; Ageno, Walter; Albers, Gregory W; Elliott, C Gregory; Hiatt, William R; Halperin, Jonathan L; Maynard, Gregory; Steg, P Gabriel; Weitz, Jeffrey I; Spiro, Theodore E; Lu, Wentao; Marsigliano, Jessica; Raskob, Gary E; Barnathan, Elliot S

Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study

住院心力衰竭患者的延长血栓预防:MAGELLAN 研究的事后分析

Spyropoulos, Alex C; Raskob, Gary E; Spiro, Theodore E; Lu, Wentao; De Sanctis, Yoriko; Albanese, John; Mebazaa, Alexandre; Barnathan, Elliot S

Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients

无症状近端深静脉血栓形成与急性重症患者死亡率之间的关联

Raskob, Gary E; Spyropoulos, Alex C; Cohen, Alexander T; Weitz, Jeffrey I; Ageno, Walter; De Sanctis, Yoriko; Lu, Wentao; Xu, Jianfeng; Albanese, John; Sugarmann, Chiara; Weber, Traci; Lipardi, Concetta; Spiro, Theodore E; Barnathan, Elliot S

Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER

利伐沙班用于住院治疗后延长血栓预防的获益风险:来自 MAGELLAN 和 MARINER 研究的汇总分析

Raskob, Gary E; Spyropoulos, Alex C; Spiro, Theodore E; Lu, Wentao; Yuan, Zhong; Levitan, Bennett; Suh, Eunyoung; Barnathan, Elliot S